A Multi-Centered, Open Label Trial on the Safety and Efficacy of Methylsulfonylmethane in the Treatment of Seasonal Allergic Rhinitis
Barrager E, Veltmann JR, Schauss AG, Schiller RN
Fifty participants completed the study. They consumed 2,600 mg of MSM orally per day or 30 days. Clinical respiratory symptoms and energy levels were evaluated by a Seasonal Allergy Symptom Questionnaire at the beginning of the study and again on days-7, 14, 21 and 30. Immune and inflammatory reactions were also determined by laboratory tests. After one week, the frequency of upper respiratory signs and symptoms (e.g., runny nose, watery and itchy eyes, nasal obstruction, paroxysmal sneezing) were significantly improved compared to initial levels. At the three-week mark, participants also had significant improvements in lower respiratory symptoms (e.g., coughing, shortness of breath and other lung or chest symptoms). All respiratory improvements were maintained through the 30-day visit. Energy levels increased significantly by day-14, an increase that continued through day-30. Minimal side effects were associated with use of MSM.